Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
34.74
-1.45 (-4.01%)
At close: Jun 27, 2025, 4:00 PM
34.79
+0.05 (0.14%)
After-hours: Jun 27, 2025, 4:07 PM EDT
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$223,823
Profits / Employee
-$134,869
Market Cap
3.84B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZLAB News
- 15 days ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
- 26 days ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 4 weeks ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 4 weeks ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire
- 4 weeks ago - Zai Lab Limited Is Well Positioned For Long-Term Growth - Seeking Alpha
- 5 weeks ago - Zai Lab Limited: Banking On Chinese Pharma Growth - Seeking Alpha
- 5 weeks ago - Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire
- 6 weeks ago - Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript - Seeking Alpha